Skip to content Skip to footer
Subscribe Now
NEWS

argenx to Acquire Forte Biosciences for $2.2B

Shots: argenx has entered into a definitive agreement to acquire Forte Biosciences, strengthening argenx’s innovative immunology portfolio with FB102 As per the deal, argenx will acquire Forte Biosciences for $77/share in cash, representing a total equity value of ~$2.2B; closing is expected in Q3’26 FB102 is an anti-CD122 antibody showing clinical PoC in vitiligo & celiac disease, with…
4 days ago

Read more

NEWS

Dassault Systèmes to Acquire ArisGlobal for ~$2B

Shots: Dassault Systèmes has entered into a definitive agreement to acquire ArisGlobal, creating the industry’s first unified intelligence platform As per the deal, Dassault will acquire ArisGlobal for ~$1.8B at closing in cash & ~$200M in additional payments linked to multi-year AI-related revenue milestones; closing is expected in H2’26 Acquisition will advance Dassault Systèmes’ ambition to…
July 23, 2026

Read more

NEWS

Repligen to Acquire BioLife for ~$1.5B

Shots: Repligen has entered into a definitive agreement to acquire BioLife Repligen will acquire BioLife for an enterprise value of ~$1.5B, with BioLife stockholders receiving $11.25 per share in cash plus 0.1442 Repligen shares, representing total consideration of $31/share, comprising 64% stock & 36% cash Acquisition is expected to fast-track Repligen’s leadership & customer solutions…
July 23, 2026

Read more

Personalis
NEWS

Tempus AI to Acquire Personalis for ~$1.5B

Shots: Tempus AI has entered into a definitive agreement to acquire Personalis, expanding Tempus' capabilities in minimal residual disease (MRD) As per the deal, Personalis shareholders will receive $16.25 per share, valuing the company at an enterprise value of $1.5B, net of Tempus AI’s existing ownership interest; closing expected in late 2026 or early 2027…
July 21, 2026

Read more

NEWS

Samsung Biologics to Acquire PolyPeptide for ~$1.8B

Shots: Samsung Biologics has launched an all-cash public tender offer to acquire 100% of the fully diluted share capital of PolyPeptide, expanding its capabilities beyond antibodies & ADCs to include peptide therapeutics As per the deal, PolyPeptide will receive CHF 44.31 (~$54.8) in cash per share, representing an implied equity value of ~CHF 1.46B (~$1.8B);…
July 20, 2026

Read more

NEWS

Eli Lilly to Acquire AtaiBeckley for $3.8B

Shots: Eli Lilly has entered into a definitive agreement to acquire AtaiBeckley, incl. its asset, BPL-003 (mebufotenin benzoate) & VLS-01 (buccal film formulation of DMT) to treat treatment-resistant depression; closing expected in Q3’26 Lilly will acquire AtaiBeckley for $6.75/share, plus a CVR of ~$2.5/share tied to development & regulatory milestones for BPL-003 & VLS-01. The…
July 16, 2026

Read more

Crinetics
NEWS

Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for ~$10B

Shots: Vertex has entered into a definitive agreement to acquire Crinetics, incl. its assets Palsonify (paltusotine) & atumelnant, accelerating Vertex’s revenue growth and enhancing its long-term earnings profile As per the deal, Vertex to acquire Crinetics for $85/share in cash, representing the total equity value of ~$10B, or ~$8.8B net of estimated cash acquired Palsonify (QD, PO)…
July 7, 2026

Read more

NEWS

Novartis to Acquire Myricx Bio for ~$1.5B

Shots: Novartis has entered into an agreement to acquire Myricx Bio, strengthening Novartis’ oncology pipeline & advancing next-generation targeted drug conjugates with novel payload mechanisms Myricx is developing ADCs, using NMT inhibitor (NMTi) payloads designed to disrupt key cancer cell processes, with preclinical data showing broad activity across solid tumors, incl. TOPO-1-resistant models As per…
July 6, 2026

Read more

Load more